Recombinant Vaccines Market Research Report – Forecast to 2027

Recombinant Vaccines Market Information: By Product (Subunit Recombinant and Attenuated Recombinant Vaccines), by Disease (Cancer, Pneumococcal Disease, Hepatitis B, and DPT), and End-Users (Pediatrics, Adults, and Veterinary) – Forecast Till 2027

ID: MRFR/Pharma/4672-HCR | | Region: Global | 100 pages

Recombinant Vaccines Market Scenario


The recombinant vaccines market is projected to exhibit a CAGR of 6.8% during the forecast period. Vaccines that are produced using the recombinant DNA technology or genetic engineering are called recombinant vaccines. The recombinant vector vaccine strategy enables triggering of T- cells and antigens, thus generating a strong cell-mediated immune response in the body against that particular immunogen. The recombinant vaccines market is majorly driven by increasing technical advanced devices, increasing number of regulatory approvals, the high prevalence of infectious diseases, and growing penetration of key market players. Furthermore, raising awareness of healthcare, favorable reimbursement policies, increasing innovations in research and development of drugs, and vaccines, as well as rising average income of individuals, are fueling the recombinant vaccines market growth. However, factors such as high cost of vaccines, risks associated with live attenuated vaccines, as well as sore throat irritability after vaccine administration and stringent regulatory policies are likely to hamper the growth of the market. Lack of proper health care infrastructure, as well as awareness regarding pathogen-related diseases in middle-income countries, are a major challenge to the market growth.


Market Players



  • Abiomed

  • Emergent Bio Solutions, Inc.

  • GlaxoSmithKline

  • Johnson & Johnson

  • Sanofi Pasteur SA

  • Serum Institute of India Pvt. Ltd

  • Mitsubishi Tanabe Pharma Corporation

  • Daiichi Sankyo

  • Pfizer, Inc.


Market Segmentation   


The recombinant vaccines market is segmented on the basis of product type, diseases, and end-user. According to the product, the recombinant vaccines market is segmented into subunit recombinant vaccines, attenuated recombinant vaccines, and vector recombinant vaccines,


Considering the disease type, the recombinant vaccines market is segmented into pneumococcal disease, cancer, hepatitis B, influenza, DPT, and others.


On account of the end-user, the recombinant vaccines market is segmented into hospitals & clinics, pediatrics, adults, veterinary, and others. Veterinary is further segmented to poultry and livestock.


Based on the region the recombinant vaccines market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.


Recombinant Vaccines Market Share (%), by Region, 2017 Recombinant Vaccines Market Share


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis


Regional Market Summary


Americas is the global leader in recombinant vaccines market owing to increasing advances in molecular biology and genetic engineering techniques as well as increasing prevalence of infectious diseases.  Additionally, factors such as increasing government initiatives and funding for research, development of advanced medical treatment options, and rising demand for technologically advanced treatment are likely to enhance the growth of recombinant vaccines market in the American region. For instance, According to stats presented in the Centers for Disease Control and Prevention report in the year 2017, around 49.9% of the children between the ages of 6 months to 17 years in the U.S. received an influenza vaccine. Due to the alarming rate of diseases associated with opportunistic pathogen developed countries are introducing compulsory immunization program. Raising global burden of cancer has also led a lot of key players to invest their time and money to come up with solutions to curb this problem. For instance, The vaccine therapy with or without trastuzumab as well as GM-CSF vaccine for the treatment of breast cancer is in phases II clinical trial. Green signal from regulatory bodies for these vaccines will further boost up the recombinant vaccines market growth


Europe is the second largest market and holds a healthy share in the recombinant vaccines market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure along with an alarming rate of cancer and infectious diseases. Furthermore, Lots of established key players in this region export their products to the developing nation. For instance, the European Commission stated that the R&D spending by the pharmaceuticals and biotechnology sectors grew by 8.7% in 2014. This investment in R&D along with the ongoing legislative reforms is expected to have a positive impact on the recombinant vaccines market.


Asia Pacific is expected to be the fastest growing market owing to the faster adaptation of healthcare technology, increasing inpatient pool due to cancer and infectious diseases, government initiatives to increase the healthcare quality, favorable insurance, and reimbursement policies. Key players have set up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia thus, boosting the growth of recombinant vaccines market. Government is also taking several initiatives to spread awareness in the low-income areas. National Immunization Program In India has helped people below the poverty line get immunized against polio as well as DPT. However, on the other hand, factor such as lack of skilled healthcare professionals may slow down the recombinant vaccines market growth during the forecast period.


The Middle East and Africa is expected to show the least growth in the recombinant vaccines market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers. However, this area has the possibility to grow during the forecast period as due to increasing outbreak of new opportunistic pathogen associated diseases like Ebola, Zika Virus, and Hepatitis B government along with some key planners have set up their R&D centers in this region.


Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Research Methodology:


 Recombinant Vaccines Market


Source: World Health Organization, Centers for Disease Control and Prevention, American Heart Association, National Institute of Health, American College of Cardiology, European Heart Network, expert interview, annual report, white paper, company presentation and market research future analysis


Market Segmentation


Recombinant Vaccines Market, by Type



  • Subunit recombinant vaccines

  • Attenuated recombinant vaccines

  • Vector recombinant vaccines


Recombinant Vaccines Market, by Disease



  • Pneumococcal Disease

    • Cancer

    • Hepatitis B

    • Influenza

    • DPT

    • Others




Recombinant Vaccines Market, by End-User



  • Hospitals & Clinics

  • Pediatrics

  • Adults

  • Veterinary

  • Poultry

  • Livestock

  • Others



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   6.8% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product type, Diseases, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abiomed, Emergent Bio Solutions, Inc., GlaxoSmithKline, Johnson & Johnson, Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo, Pfizer, Inc.
  Key Market Opportunities

  • Raising awareness of healthcare, favorable reimbursement policies
  • Increasing innovations in research and development of drugs, and vaccines
  • Rising average income of individuals
  •   Key Market Drivers

  • Increasing technical advanced devices
  • Increasing number of regulatory approvals
  • The high prevalence of infectious diseases
  • Growing penetration of key market players


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The global recombinant vaccines market is expected to expand at 6.8% CAGR from 2020 to 2027.

    High prevalence of diseases and large number of approvals are major drivers of the global recombinant vaccines market.

    High costs of vaccines and huge risks associated with attenuated vaccines are factors which can hamper the global recombinant vaccines market.

    The global recombinant vaccines market is led by the Americas due to rapid strides in molecular biology in the region.

    Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Daiichi Sankyo, Serum Institute of India Pvt. Ltd, Emergent Bio Solutions, Inc., Sanofi Pasteur SA, and Abiomed are major players in the global recombinant vaccines market.

    Table of Content

    1. Report Prologue

    2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    6. Global Recombinant Vaccines Market, by Route of Administration

    6.1 Introduction

    6.2 Intramuscular and Subcutaneous Administration

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    6.3 Oral Administration

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    6.4 Other Routes of Administration

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    7. Global Recombinant Vaccines Market, by Type

    7.1 Introduction

    7.2 Subunit recombinant vaccines

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    7.3 Attenuated recombinant vaccines

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    7.4 Vector recombinant vaccines

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    8. Global Recombinant Vaccines Market, by Disease

    8.1 Introduction

    8.2 Pneumococcal Disease

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    8.3 Cancer

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    8.4 Hepatitis B

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    8.5 Influenza

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    8.6 HPV (Human papillomavirus)

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    8.7 DPT

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    8.8 Others

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    9. Global Recombinant Vaccines Market, by End-User

    9.1 Introduction

    9.2 Hospitals & Clinics

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    9.3 Pediatrics

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    9.4 Adults

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    9.5 Veterinary

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    9.5.1 Poultry

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    9.5.2 Livestock

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    9.5.3 Others

    • Market Estimates & Forecast, 2020–2027

    • Market Estimates & Forecast, by Region/Country, 2020–2027

    10 Global Recombinant Vaccines Market, by Region

    10.1 Introduction

    10.2 Americas

    • Market Estimates & Forecast, by Region, 2020–2027

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.2.1 North America

    • Market Estimates & Forecast, by Country, 2020–2027

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.2.1.1 U.S.

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.2.1.2 Canada

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.2.2 South America

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3 Europe

    • Market Estimates & Forecast, by Region, 2020–2027

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1 Western Europe

    • Market Estimates & Forecast, by Country, 2020–2027

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.1 Germany

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.2 France

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.3 U.K.

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.4 Italy

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.5 Spain

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.1.6 Rest of Western Europe

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.3.2 Eastern Europe

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4 Asia Pacific

    • Market Estimates & Forecast, by Country, 2020–2027

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.1 Japan

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.2 China

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.3 India

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.4 Australia

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.5 Republic of Korea

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.4.6 Rest of Asia Pacific

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5 The Middle East & Africa

    • Market Estimates & Forecast, by Region, 2020–2027

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.1 United Arab Emirates

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.2 Saudi Arabia

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.3 Oman

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.4 Kuwait

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.5 Qatar

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    10.5.6 Rest of the Middle East & Africa

    • Market Estimates & Forecast, by Type, 2020–2027

    • Market Estimates & Forecast, by Disease, 2020–2027

    • Market Estimates & Forecast, by End-User, 2020–2027

    11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    12 Company Profiles

    12.1 Astellas Pharma Inc

    12.1.1 Company Overview

    12.1.2 Route of Administration Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 CSL Limited

    12.2.1 Company Overview

    12.2.2 Route of Administration Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Emergent BioSolutions, Inc.

    12.3.1 Company Overview

    12.3.2 Route of Administration Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 GlaxoSmithKline

    12.4.1 Company Overview

    12.4.2 Route of Administration/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Johnson & Johnson (U.S.)

    12.5.1 Company Overview

    12.5.2 Route of Administration Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 Mitsubishi Tanabe Pharma Corporation

    12.6.1 Company Overview

    12.6.2 Route of Administration Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 Merck & Co., Inc.

    12.7.1 Overview

    12.7.2 Route of Administration Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Pfizer, Inc..

    12.8.1 Overview

    12.8.2 Route of Administration Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Sanofi Pasteur SA

    12.9.1 Overview

    12.9.2 Route of Administration Overview

    12.9.3 Financials

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 Serum Institute of India Pvt. Ltd

    12.10.1 Overview

    12.10.2 Route of Administration Overview

    12.10.3 Financials

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.11 Bavarian Nordic

    12.11.1 Overview

    12.11.2 Route of Administration Overview

    12.11.3 Financials

    12.11.4 Key Developments

    12.11.5 SWOT Analysis

    12.12 Mitsubishi Tanabe Pharma Corporation

    12.12.1 Overview

    12.12.2 Route of Administration Overview

    12.12.3 Financials

    12.12.4 Key Developments

    12.12.5 SWOT Analysis

    12.13 Daiichi Sankyo

    12.13.1 Overview

    12.13.2 Route of Administration Overview

    12.13.3 Financials

    12.13.4 Key Developments

    12.13.5 SWOT Analysis

    13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Pharmaceutical Industry

    14 Appendix

    LIST OF TABLES

    Table 1 Recombinant Vaccines Industry Synopsis, 2020–2027

    Table 2 Global Recombinant Vaccines Market Estimates and Forecast, 2020–2027, (USD Million)

    Table 3 Global Recombinant Vaccines Market by Region, 2020–2027, (USD Million)

    Table 5 Global Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

    Table 6 Global Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

    Table 7 Global Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

    Table 8 North America Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

    Table 9 North America Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

    Table 10 North America Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

    Table 11 US Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

    Table 12 US Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

    Table 13 US Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

    Table 14 Canada Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

    Table 15 Million)

    Table 16 Canada Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

    Table 17 Canada Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

    Table 18 South America Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

    Table 19 South America Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

    Table 20 South America Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

    Table 21 Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

    Table 22 Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

    Table 23 Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

    Table 24 Western Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

    Table 25 Western Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

    Table 26 Western Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

    Table 27 Eastern Europe Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

    Table 28 Eastern Europe Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

    Table 29 Eastern Europe Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

    Table 30 Asia Pacific Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

    Table 31 Asia Pacific Recombinant Vaccines Market by Disease, 2020–2027, (USD Million)

    Table 32 Asia Pacific Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)

    Table 33 Middle East & Africa Recombinant Vaccines Market by Type, 2020–2027, (USD Million)

    Table 34 Middle East & Africa Recombinant Vaccines Market by End-Users, 2020–2027, (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Recombinant Vaccines Market

    Figure 3 Segmentation Market Dynamics for Recombinant Vaccines Market

    Figure 4 Global Recombinant Vaccines Market Share, by Type 2020

    Figure 5 Global Recombinant Vaccines Market Share, by End-Users, 2020

    Figure 6 Global Recombinant Vaccines Market Share, by Region, 2020

    Figure 7 North America Recombinant Vaccines Market Share, by Country, 2020

    Figure 8 Europe Recombinant Vaccines Market Share, by Country, 2020

    Figure 9 Asia Pacific Recombinant Vaccines Market Share, by Country, 2020

    Figure 10 Middle East & Africa Recombinant Vaccines Market Share, by Country, 2020

    Figure 11 Global Recombinant Vaccines Market: Company Share Analysis, 2020 (%)

    Figure 12 Astellas Pharma Inc: Key Financials

    Figure 13 Astellas Pharma Inc: Segmental Revenue

    Figure 14 Astellas Pharma Inc: Geographical Revenue

    Figure 15 Emergent BioSolutions, Inc.. Key Financials

    Figure 16 Emergent BioSolutions, Inc.: Segmental Revenue

    Figure 17 Emergent BioSolutions, Inc.: Geographical Revenue

    Figure 18 Pfizer, Inc.. : Key Financials

    Figure 19 Pfizer, Inc.. : Segmental Revenue

    Figure 20 Pfizer, Inc.. : Geographical Revenue

    Figure 21 GlaxoSmithKline: Key Financials

    Figure 22 GlaxoSmithKline: Segmental Revenue

    Figure 23 GlaxoSmithKline: Geographical Revenue

    Figure 24 Mitsubishi Tanabe Pharma Corporation : Key Financials

    Figure 25 Mitsubishi Tanabe Pharma Corporation : Segmental Revenue

    Figure 26 Mitsubishi Tanabe Pharma Corporation . Geographical Revenue

    Figure 29 Bavarian Nordic. Key Financials

    Figure 30 Bavarian Nordic. Segmental Revenue

    Figure 31 Bavarian Nordic. Geographical Revenue